DIP
BIIB icon

Davis Investment Partners’s Biogen BIIB Stock Holding History

Davis Investment Partners’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$688K Sell
3,184
-396
-11% -$75.8K 0.21% 76
2026
Q1 		$656K Sell
3,580
-794
-18% -$146K 0.23% 76
2025
Q4 		$778K Buy
4,374
+71
+2% +$11.6K 0.27% 63
2025
Q3 		$664K Buy
+4,303
New +$582K 0.23% 71

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Davis Investment Partners's BIIB Position: Q2 2026 in Review

Davis Investment Partners reduced its Biogen (BIIB) stake by 11% in Q2 2026, selling an estimated $75.8K and leaving 3,184 shares worth $688K. The position accounts for 0.21% of the portfolio, ranked #76.

Davis Investment Partners first reported a position in BIIB in Q3 2025 and has held it in 4 quarters since. The position peaked at $778K in Q4 2025. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

  • Davis Investment Partners held 3,184 shares of Biogen worth $688K as of Q2 2026.
  • Davis Investment Partners sold 396 Biogen shares in Q2 2026, an estimated $75.8K.
  • Biogen made up 0.21% of Davis Investment Partners's portfolio in Q2 2026, its #76 holding.
  • Davis Investment Partners first reported a position in Biogen in Q3 2025 and has held it in 4 quarters since.
  • Davis Investment Partners's Biogen position peaked at $778K in Q4 2025.
  • 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Davis Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.